A Phase I Study of the Immune Activity and Safety of IMC-CS4 in Patients with Advanced Breast or Prostate Cancers

Full Title

Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients with Advanced, Refractory Breast or Prostate Cancer


IMC-CS4 (also called LY3022855) is an investigational anticancer drug. It is an antibody designed to trigger an immune response against cancer by binding to a protein on cancer cells called CSF1R.

The goal of this study is to see how IMC-CS4 affects the body’s immune response to cancer in patients with advanced breast cancer or prostate cancers that have continued to grow despite standard therapies. Investigators will also determine how safe IMC-CS4 is in these patients.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have advanced breast or prostate cancer that has continued to grow despite standard therapies.
  • At least 4 weeks must pass between the completion of prior therapies and entry into the study.
  • Patients must be willing to have a biopsy of their cancer before starting treatment and again during the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Karen Autio at 646-422-4632.